[go: up one dir, main page]

DK3642331T3 - Fremgangsmåde til udvidelse af T-celler og anvendelser deraf - Google Patents

Fremgangsmåde til udvidelse af T-celler og anvendelser deraf Download PDF

Info

Publication number
DK3642331T3
DK3642331T3 DK18735229.9T DK18735229T DK3642331T3 DK 3642331 T3 DK3642331 T3 DK 3642331T3 DK 18735229 T DK18735229 T DK 18735229T DK 3642331 T3 DK3642331 T3 DK 3642331T3
Authority
DK
Denmark
Prior art keywords
expanding
cells
Prior art date
Application number
DK18735229.9T
Other languages
English (en)
Inventor
Hans Grönlund
Original Assignee
Neogap Therapeutics Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1710023.1A external-priority patent/GB201710023D0/en
Priority claimed from GBGB1716978.0A external-priority patent/GB201716978D0/en
Application filed by Neogap Therapeutics Ab filed Critical Neogap Therapeutics Ab
Application granted granted Critical
Publication of DK3642331T3 publication Critical patent/DK3642331T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/10Cellular immunotherapy characterised by the cell type used
    • A61K40/11T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/20Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24Antigen-presenting cells [APC]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/40Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41Vertebrate antigens
    • A61K40/42Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/40Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41Vertebrate antigens
    • A61K40/42Cancer antigens
    • A61K40/4201Neoantigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K4/00Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • C07K4/12Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof from animals; from humans
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • C12N5/0638Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0639Dendritic cells, e.g. Langherhans cells in the epidermis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998Proteins not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00Coculture with; Conditioned medium produced by
    • C12N2502/11Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1121Dendritic cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2531/00Microcarriers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Fuel Cell (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK18735229.9T 2017-06-22 2018-06-21 Fremgangsmåde til udvidelse af T-celler og anvendelser deraf DK3642331T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1710023.1A GB201710023D0 (en) 2017-06-22 2017-06-22 T-cell expansion method and uses
GBGB1716978.0A GB201716978D0 (en) 2017-10-16 2017-10-16 T-cell expansion method and uses
PCT/EP2018/066690 WO2018234516A2 (en) 2017-06-22 2018-06-21 METHOD AND APPARATUS FOR EXPANSION OF T CELLULOCYTES

Publications (1)

Publication Number Publication Date
DK3642331T3 true DK3642331T3 (da) 2023-07-31

Family

ID=62784126

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18735229.9T DK3642331T3 (da) 2017-06-22 2018-06-21 Fremgangsmåde til udvidelse af T-celler og anvendelser deraf

Country Status (11)

Country Link
US (2) US20200140813A1 (da)
EP (2) EP3642331B1 (da)
JP (1) JP7218309B2 (da)
KR (1) KR102713342B1 (da)
CN (2) CN110785487B (da)
AU (2) AU2018287169B2 (da)
CA (1) CA3068103A1 (da)
DK (1) DK3642331T3 (da)
ES (1) ES2950653T3 (da)
FI (1) FI3642331T3 (da)
WO (1) WO2018234516A2 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL280110B2 (en) 2018-07-26 2025-07-01 Curevac Netherlands B V Cancer vaccines ready for use
GB201821207D0 (en) 2018-12-24 2019-02-06 Tcer Ab Immunotherapy therapy
CN111638329B (zh) * 2020-06-09 2021-06-01 南方医科大学 一种用于检测布鲁氏菌病elispot检测试剂盒及其应用
GB202010095D0 (en) * 2020-07-01 2020-08-12 Tcer Ab Immunotherapy
WO2022123394A1 (en) 2020-12-08 2022-06-16 Guizhou Sinorda Biotechnology Co. Ltd. Modified t cells for adoptive immunotherapy
EP4032973B1 (en) 2021-01-21 2023-07-19 Guizhou Sinorda Biotechnology CO., Ltd. Modified t cells for adoptive immunotherapy
EP4405507A4 (en) * 2021-09-20 2025-11-05 Droplet Biosciences Inc METHODS FOR DISEASE ASSESSMENT USING A DRAINAGE FLUID

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1623017T3 (da) * 2003-05-08 2011-01-10 Life Technologies Corp Frembringelse og isolering af antigenspecifikke T-celler
US20080171059A1 (en) * 2006-08-07 2008-07-17 Shanshan Wu Howland Methods and compositions for increased priming of t-cells through cross-presentation of exogenous antigens
US9107858B2 (en) * 2007-12-05 2015-08-18 Wisconsin Alumni Research Foundation Dendritic cell targeting compositions and uses thereof
WO2011053331A1 (en) * 2009-11-02 2011-05-05 Orbis Health Solutions Llc Vaccine compositions and methods of use
CN110200997A (zh) * 2011-03-23 2019-09-06 弗雷德哈钦森癌症研究中心 用于细胞免疫治疗的方法和组合物
WO2012159643A1 (en) * 2011-05-24 2012-11-29 Biontech Ag Individualized vaccines for cancer
AU2013351542B2 (en) 2012-11-28 2018-08-09 BioNTech SE Individualized vaccines for cancer
KR102341899B1 (ko) * 2013-04-07 2021-12-21 더 브로드 인스티튜트, 인코퍼레이티드 개인맞춤화 신생물 백신을 위한 조성물 및 방법
EP3193892A4 (en) * 2014-09-14 2018-09-12 Washington University Personalized cancer vaccines and methods therefor
JP6599450B2 (ja) * 2014-10-02 2019-10-30 アメリカ合衆国 がん特異的突然変異に対し抗原特異性を有するt細胞を単離する方法
WO2016077215A2 (en) * 2014-11-10 2016-05-19 Yale University Modular nanodevices for smart adaptable vaccines
WO2016187508A2 (en) * 2015-05-20 2016-11-24 The Broad Institute Inc. Shared neoantigens
WO2017087692A1 (en) * 2015-11-18 2017-05-26 The University Of North Carolina At Chapel Hill Antigen capturing nanoparticles for use in cancer immunotherapy
WO2017096304A1 (en) 2015-12-04 2017-06-08 Board Of Regents, The University Of Texas System Slc45a2 peptides for immunotherapy
EP3182125A1 (en) * 2015-12-16 2017-06-21 Ab Tcer T-cell reactivity platform

Also Published As

Publication number Publication date
US20200140813A1 (en) 2020-05-07
KR20200020904A (ko) 2020-02-26
FI3642331T3 (fi) 2023-07-24
AU2025201021A1 (en) 2025-03-06
EP3642331B1 (en) 2023-05-24
JP7218309B2 (ja) 2023-02-06
ES2950653T3 (es) 2023-10-11
WO2018234516A2 (en) 2018-12-27
CN110785487B (zh) 2025-08-29
CA3068103A1 (en) 2018-12-27
AU2018287169B2 (en) 2024-11-14
CN120555350A (zh) 2025-08-29
CN110785487A (zh) 2020-02-11
JP2020524514A (ja) 2020-08-20
WO2018234516A3 (en) 2019-02-14
KR102713342B1 (ko) 2024-10-02
EP4248980A3 (en) 2023-12-06
AU2018287169A1 (en) 2020-01-16
EP3642331A2 (en) 2020-04-29
US20250206793A1 (en) 2025-06-26
EP4248980A2 (en) 2023-09-27

Similar Documents

Publication Publication Date Title
DK3568494T3 (da) Fremgangsmåder og sammensætninger til markering af celler
DK3630761T3 (da) Kras-g12c-inhibitorer og fremgangsmåder til anvendelse af disse
DK3750418T3 (da) Aerosolgenereringsenhed og fremgangsmåde til styring af samme
DK3402483T3 (da) Fremgangsmåder og sammensætninger til aktivering af gamma-delta-T-celler
DK3398022T3 (da) Systemer og fremgangsmåder til tilpasning af uav-bane
DK3259386T3 (da) Systemer og fremgangsmåder til udførelse af immunoassays
DK3132247T3 (da) Fremgangsmåder, kits og apparat til udvidelse af en cellepopulation
DK3536008T3 (da) System og fremgangsmåde til udløsning af strålegenopretning
DK3469338T3 (da) Billedbaserede systemer og fremgangsmåder til cellesortering
DK3426109T3 (da) Samling og fremgangsmåde til opskumning af fluid
DK3346629T3 (da) Fremgangsmåde og enhed til overførsel af informationer
DK3642331T3 (da) Fremgangsmåde til udvidelse af T-celler og anvendelser deraf
DK3753301T3 (da) Fremgangsmåde og indretning til opnåelse af celleoplysninger
DK3519572T3 (da) Forbindelser og fremgangsmåder til reduktion af tau-ekspression
DK3704227T3 (da) Sammensætning og fremgangsmåde
DK3394259T3 (da) Sammensætninger og fremgangsmåder til reducering af tau-ekspression
DK3188051T3 (da) Systemer og fremgangsmåder til generering af søgeskabeloner
DK3441381T3 (da) Fremgangsmåde til fremstilling af methanol og indretning til fremstilling af methanol
DK3717851T3 (da) Fremgangsmåde og anordning til tørring af plader
DK3393688T3 (da) Fremgangsmåde og indretning til genindvinding af salt
DK3397748T3 (da) Fremgangsmåde til dyrkning og konservering af Eubacterium hallii
DK3325422T3 (da) Fremgangsmåde og indretning til fremstilling af et ekspanderet granulat
DK3541947T3 (da) Fremgangsmåde til fremstilling af elektrokompetente gærceller og fremgangsmåde til anvendelse af cellerne
DK3404258T3 (da) Systemer og fremgangsmåder til stabilisering af effektgenerering
DK3821770T3 (da) Anordning og fremgangsmåde til opskumning af fluid